Comments
Drug firm, Lupin, on Tuesday, said that it has received four observations in the Establishment Inspection Report (EIR) given by the US health regulator, following the closure of pharmacovigilance inspection.
“The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide. The inspection closed with four observations,” the company said in a regulatory filing.
Lupin has received the EIR from the United States Food and Drug Administration (USFDA) for the Post-marketing Adverse Drug Experience (PADE) inspection, indicating successful closure of the inspection, the filing added.
Read more: Indian drug-companies too hit in US lawsuit on price manipulation
The inspection was conducted at its global pharmacovigilance group DSRM (Drug Safety & Risk Management) based in Mumbai, between January 14-18, 2019, the file said.
The USFDA issues an EIR to an establishment that is the subject of an FDA (Food and Drug Administration) or FDA-contracted inspection following the closure of the inspection.
Shares of Lupin Ltd were trading 0.18 per cent higher at ₹802.80 a piece on BSE (Bombay Stock Exchange).
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.